Group 1 - The core point of the news is that 博拓生物's stock price has decreased by 5.01%, currently trading at 39.05 CNY per share, with a total market capitalization of 58.31 billion CNY [1] - 博拓生物, established on November 28, 2008, specializes in the research, production, and sales of POCT diagnostic reagents, with 92.91% of its revenue coming from diagnostic reagent products [1] - The trading volume for 博拓生物 reached 2.27 billion CNY, with a turnover rate of 3.76% [1] Group 2 - From the perspective of major shareholders, 广发价值核心混合A (010377) holds 2.56% of 博拓生物's circulating shares, with a current floating loss of approximately 563.17 million CNY [2] - The fund has achieved a return of 68.54% year-to-date and 114.67% over the past year, ranking 147 out of 8194 and 129 out of 7963 respectively [2] - The fund manager, 吴远怡, has been in charge for 4 years and 333 days, with a total asset scale of 204.78 billion CNY [3] Group 3 - In the second quarter, 广发价值核心混合A (010377) held 423.6 million shares of 博拓生物, representing 2.75% of the fund's net value, making it the eighth largest holding [4] - The current floating loss for the fund regarding 博拓生物 is estimated at 872.62 million CNY [4]

证券代码：688468 证券简称：科美诊断 科美诊断技术股份有限公司 二零二五年九月 三、 股东及股东代理人参加股东会依法享有发言权、质询权、表决权等 权利。股东及股东代理人参加股东会应认真履行其法定义务，不得侵犯公司和其 他股东及股东代理人的合法权益，不得扰乱股东会的正常秩序。 四、 股东及股东代理人要求在股东会现场会议上发言的，应于股东会召 开前一天向大会会务组进行登记。大会主持人根据会务组提供的名单和顺序安排 发言。 现场要求提问的股东及股东代理人，应当按照会议的议程举手示意，经会议 主持人许可后方可提问。有多名股东及股东代理人同时要求提问时，先举手者先 提问；不能确定先后时，由主持人指定提问者。 会议进行中只接受股东及股东代理人发言或提问。发言或提问应围绕本次会 议议题进行，简明扼要，时间不超过5分钟。发言或提问时需说明股东名称及所 持股份总数。每位股东及股东代理人发言或提问次数不超过2次。 科美诊断技术股份有限公司（688468） 2025年第一次临时股东会会议资料 五、 股东及股东代理人要求发言时，不得打断会议报告人的报告或其他 股东及股东代理人的发言。在股东会进行表决时，股东及股东代理人不再进行 ...